Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4030 - Naturally occurring immune response against biologically and clinically relevant targets


09 Oct 2016


Poster display


Juan Marquez


Annals of Oncology (2016) 27 (6): 462-468. 10.1093/annonc/mdw385


J.P. Marquez1, S. Carrillo2, A. Suplee-Rivera2, E. Ramos1, P.A. Lucero-Diaz2, A. Camacho-Hernandez2, J.A. Matute-Briseno2, R. Soto-Soto2

Author affiliations

  • 1 Oncology, Tumor Vaccine Group University of Washington, 98109-4714 - Seattle/US
  • 2 Immuno-oncology, CENTRO DE INVESTIGACION DEL CANCER EN SONORA, 85040 - Sonora/MX


Abstract 4030


Few studies evaluate the immunogenicity of biological relevant targets in tumors with high-world prevalence and early relapse such as ovarian, triple negative breast cancer (TNBC), multiple myeloma (MM), etc. Some tumor targets are immunogenic but are not relevant for tumor survival such as CEA, CA-125, CA-19-9, etc. and have failed in vaccines clinical trials. Only a few studies focus on the biological and clinical relevance of tumor antigens such as MUC1, Her-2, etc. Aberrant up-regulation of some proteins that are involved in cancer relapse has shown to be a mechanism by which some auto-proteins become immunogenic and potentially targets of both humoral and cellular adaptive immune response. We evaluated whether putative relevant proteins that are found in high incidence of several cancers and associated with poor prognosis could be recognized by the humoral immune response. We further interrogate if the humoral immune response against these proteins may predict relapse and overall survival.


Four broad-spectrum proteins known to be overexpressed in several tumors and associated with early relapse were identified by systematic reviews. Indirect peptide ELISA was used to evaluate humoral immune response using all predicted peptides from these proteins. 50 stage IV cancer patients and 50 age-matched controls were studied. We identified those MHC-I and MHC-II peptides using computer-based algorithms from Ape-1, Fascin, RCAS1 and VCP.


Fascin and VCP peptide mixes are immunogenic in all cancer-interrogated patients and in some controls. Antibody responses were significantly elevated in cancer patient's sera when compared to controls (Ape-1 p = ns, Fascin p = 0.0016, RCAS1 p = ns and VCP p  0.38 against at least 2 peptides for 2 proteins had better overall survival (p = 0.005).


Discussion: All tumors studied reacted by peptide indirect ELISA at least against 2 peptides of overexpressed proteins involved in important biologic pathways and this is the first approach to design a broad spectrum multi-peptide vaccine to prevent relapse. Humoral immune response may also predict the clinical outcomes in malignancies that tend to relapse in short period of time.

Clinical trial identification


Legal entity responsible for the study

Centro de Investigación de Cáncer en Sonora


Centro de Investigación de Cáncer en Sonora


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings